Boceprevir-based Therapy to Rescue HCV Genotype 1/HBV Infected Patients Refractory to Combination Therapy
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to explore the efficacy and safety of boceprevir -based triple
therapy to rescue HCV genotype 1 (HCV GT1)/HBV dually infected patients refractory to
previous peginterferon (PEG-IFN) plus ribavirin (RBV) combination therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Kaohsiung Medical University Chung-Ho Memorial Hospital